Vertex Pharmaceuticals (VRTX) Stock Price
Vertex Pharmaceuticals Price
Vertex Pharmaceuticals (VRTX) Stock | ISIN US92532F1003 | WKN 882807. The current Vertex Pharmaceuticals stock price is 440.23 USD (2026). Revenue is 13.33 B USD. Net income is 5.17 B USD. The P/E ratio is 21.96. Market capitalization is 111.7 B USD. Vertex Pharmaceuticals operates in the Health sector.
Vertex Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Vertex Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vertex Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vertex Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Vertex Pharmaceuticals Price |
|---|
Vertex Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Vertex Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Vertex Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vertex Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vertex Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Vertex Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vertex Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Vertex Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Vertex Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Vertex Pharmaceuticals business model & stock analysis
Vertex Pharmaceuticals SWOT Analysis
Strengths
Vertex Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company holds a strong portfolio of innovative and breakthrough drugs, particularly for the treatment of cystic fibrosis. These drugs have not only garnered significant market share but have also improved the quality of life for patients worldwide.
Secondly, Vertex Pharmaceuticals has established strong relationships with healthcare professionals, research institutions, and advocacy groups. These collaborations enable the company to stay at the forefront of scientific advancements and ensure the development of effective treatment options.
Lastly, the company demonstrates a robust financial position with steady revenue growth and a solid pipeline of potential drugs. This financial strength allows Vertex Pharmaceuticals to invest in research and development, ensuring continued innovation and expansion of its product offerings.
Weaknesses
Despite its strengths, Vertex Pharmaceuticals Inc also faces certain weaknesses. One major weakness is its heavy reliance on a few flagship drugs, especially those targeting cystic fibrosis. As a result, the company is exposed to market risks and regulatory uncertainties specifically associated with these drugs. Any setbacks or challenges related to these products could significantly impact the company's revenues and growth prospects.
Additionally, Vertex Pharmaceuticals operates in a highly competitive industry. Competition from other pharmaceutical companies, both established players and emerging biotech firms, poses a continuous threat to its market position. This necessitates a continual focus on innovation and differentiation to remain ahead of the competition.
Opportunities
The pharmaceutical industry offers numerous opportunities for Vertex Pharmaceuticals to further expand and solidify its position. The growing global prevalence of cystic fibrosis and other genetic disorders presents an opportunity for increased demand for the company's existing and future drugs. By strategically leveraging its expertise in disease biology, Vertex can identify new therapeutic targets and develop novel treatments for other genetic diseases.
Moreover, the increasing adoption of precision medicine and personalized therapies presents a favorable environment for Vertex Pharmaceuticals. The ability to tailor treatments to individual patients based on their genetic makeup aligns with the company's core competency in developing targeted therapies.
Threats
Despite the opportunities, Vertex Pharmaceuticals Inc faces potential threats that could impact its growth and profitability. One significant threat is the intense scrutiny and regulation of the pharmaceutical industry. Stricter regulations, pricing pressures, and reimbursement challenges can limit market access and profitability for new drugs.
Another threat comes from potential legal and intellectual property issues. Vertex operates in multiple countries, each with its own patent laws and litigation risks. Any legal disputes or challenges to its patents can lead to substantial financial losses and a loss of market exclusivity for certain drugs.
Furthermore, the current global economic landscape and geopolitical uncertainties can also impact the company's operations, including manufacturing costs, supply chain disruptions, and market demand fluctuations.
Vertex Pharmaceuticals Segments
Vertex Pharmaceuticals Revenue by Segment (1/5)
Max
Details
Vertex Pharmaceuticals Revenue by Segment (2/5)
Max
Details
Vertex Pharmaceuticals Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Vertex Pharmaceuticals Revenue by Segment (4/5)
Max
Details
Vertex Pharmaceuticals Revenue by Segment (5/5)
Max
Details
Vertex Pharmaceuticals Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Vertex Pharmaceuticals Eulerpool Fair Value
Vertex Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Vertex Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Vertex Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Vertex Pharmaceuticals Earnings Calls
Vertex Pharmaceuticals Earnings Estimates
Vertex Pharmaceuticals Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/4/2026 | 4.41USD | 3.09 BUSD | 2026 Q1 |
| 2/12/2026 | 5.2USD | 3.24 BUSD | 2025 Q4 |
| 2/4/2026 | 5.19USD | 3.24 BUSD | 2025 Q4 |
| 4/29/2024 | 4.24USD | 2.56 BUSD | 2024 Q1 |
| 2/5/2024 | 4.17USD | 2.57 BUSD | 2023 Q4 |
| 8/2/2023 | 3.98USD | 2.4 BUSD | 2023 Q2 |
| 5/3/2023 | 3.9USD | 2.34 BUSD | 2023 Q1 |
| 1/24/2023 | 3.63USD | 2.33 BUSD | 2022 Q4 |
| 10/27/2022 | 3.72USD | 2.26 BUSD | 2022 Q3 |
| 8/4/2022 | 3.55USD | 2.16 BUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Vertex Pharmaceuticals stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Vertex Pharmaceuticals shareholder structure
| % | Name |
|---|---|
11.32435% | |
9.40333% | |
6.34885% | |
5.57808% | |
4.64103% | |
2.48481% | |
2.33673% | |
2.08768% | |
1.89713% | |
1.72565% |
Vertex Pharmaceuticals Executives and Management Board
Dr. Reshma Kewalramani
(52)President, Chief Executive Officer, Director · since 2018
Mr. Charles Wagner
(57)Chief Financial Officer, Chief Operating Officer, Executive Vice President
Dr. David Altshuler
(60)Executive Vice President, Chief Scientific Officer · since 2012
Dr. Ourania Tatsis
(55)Executive Vice President, Chief Regulatory and Quality Officer
Dr. Jeffrey Leiden
(69)Executive Chairman of the Board · since 2009
Vertex Pharmaceuticals Supply Chain
Frequently asked questions about Vertex Pharmaceuticals
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals stock
Vertex Pharmaceuticals Peer Group
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Vertex Pharmaceuticals
Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.